Nina Capital

MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The company's platform streamlines processes by offering configurable workflows, a form builder for capturing complex and structured therapy-specific data, and tools for task management and tracking. Additionally, it integrates with machine learning libraries to enhance collaboration between manufacturers and physicians regarding requests for investigational medicines. MedaSystems focuses on various access programs, including expanded access, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby empowering global initiatives in the healthcare sector.

Sonar is a healthcare company focusing on the proactive identification and intervention of mental health challenges in youth.

Connective Health operates as a healthcare technology company specializing in electronic health record (EHR) summarization. Their core product is a clinical-grade summary for each patient within the EHR system, accompanied by real-time insights. This solution aims to streamline care provider workflows by condensing patients' medical history, diagnoses, medications, and behavioral care insights into an easily digestible format, thereby facilitating more efficient and accurate treatment decisions.

Selfii is a healthcare technology company that operates a data collection platform. It aggregates and structures patient-consented healthcare data from various sources like electronic health records and patient-generated data. This data is then transformed into a comprehensive medical knowledge graph, enabling researchers and healthcare professionals to accelerate clinical research, AI development, and app creation.

Noah Labs develops innovative technology aimed at the early detection of cardiovascular diseases through voice analysis. Utilizing advanced machine learning software, the company has created a digital health platform that allows patients to record their voices using a smartphone. This platform incorporates patient monitoring and digital biomarkers, providing personalized and predictive virtual care in the comfort of their homes. By focusing on voice-based diagnostics, Noah Labs seeks to empower individuals with cardiovascular conditions to lead healthier and longer lives.

Segmed, Inc. is a company based in Menlo Park, California, that specializes in providing cloud-based solutions for accessing curated and anonymized radiology data. Established in 2019, Segmed offers customized datasets tailored to the specific needs of its clients in the pharmaceutical and medical device sectors. Its platform supports the development of predictive models and enhances patient recruitment and data management, facilitating research and regulatory processes within the life sciences and technology industries. By focusing on de-identified and structured medical imaging data, Segmed aims to improve early disease detection and prediction while ensuring that findings are accessible and representative of diverse populations.

Sober Sidekick is a developer of a mobile application and telehealth platform focused on aiding individuals in their journey towards sobriety. The company provides a social networking environment where users can connect with others who share similar experiences and challenges related to addiction. By offering features such as a sobriety tracker and access to various addiction recovery resources, Sober Sidekick aims to support users in quitting alcohol and drugs. The platform fosters a judgment-free space that encourages accountability and community engagement, enhancing the recovery experience for those striving to maintain their sobriety.

Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.

Quantivly, Inc., established in 2019 and headquartered in Somerville, Massachusetts, specializes in developing artificial intelligence-based solutions tailored for the field of radiology. The company focuses on enhancing data liquidity and providing analytical tools that enable radiology providers to make informed decisions, thereby increasing access to medical imaging services. Quantivly's platform is designed to manage and analyze MRI imaging workflows by cleaning and harmonizing scanner data, resulting in a vendor-neutral and comprehensive source of operational knowledge. This innovative approach supports radiology departments and imaging centers in utilizing data analytics to improve decision-making, facilitate new research initiatives, and enhance the overall patient experience in healthcare.

Ryver specializes in developing software solutions for data collaboration and sharing while prioritizing privacy. The company's platform enables clients to generate synthetic data from original datasets efficiently, particularly in the medical field, where it facilitates the rapid access to radiology cases. By automating the evaluation of privacy and utility of synthetic data, Ryver eliminates the need for manual compliance processes, significantly reducing the time and cost associated with data acquisition. Their technology seamlessly integrates into various data warehouses, cloud environments, and IT infrastructures, thereby providing detailed compliance and usage information. This innovative approach supports medical AI teams in creating high-quality radiology images with annotations, enhancing both speed and effectiveness in medical data utilization.

MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The company's platform streamlines processes by offering configurable workflows, a form builder for capturing complex and structured therapy-specific data, and tools for task management and tracking. Additionally, it integrates with machine learning libraries to enhance collaboration between manufacturers and physicians regarding requests for investigational medicines. MedaSystems focuses on various access programs, including expanded access, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby empowering global initiatives in the healthcare sector.

QuantHealth is a company focused on enhancing drug development through artificial intelligence-based software. This software is designed to conduct patient-centric simulations that accelerate and de-risk the drug development process. By integrating diverse data points from the clinical and drug development landscape, QuantHealth predicts patient responses to both existing and new therapies. This capability allows pharmaceutical and biotechnology firms to explore various scenarios within their clinical trials, optimizing trial designs and improving the likelihood of successful outcomes. Ultimately, QuantHealth's solutions facilitate the discovery of new clinical opportunities and strategies for optimizing drug development.

Lillian is building a nationwide network of health facilities in Germany.

Basys.ai is a technology company focused on automating prior authorization and utilization management processes for health plans and payers. Utilizing a proprietary AI-based platform, Basys.ai streamlines the encoding and digitization of payer policies through machine learning, significantly reducing the time needed for implementation. The platform enhances communication between patients and healthcare providers, integrates electronic health records, and employs algorithms aimed at improving care quality. By facilitating these processes, Basys.ai helps health plans lower administrative and medical costs while enabling organizations to effectively monitor patient health records and optimize patient outcomes.

Alfie Health is a virtual obesity management clinic that focuses on sustainable weight loss through a combination of precision medicine and behavioral change. Utilizing proprietary AI clinical decision support technology, Alfie Health continuously analyzes patient data, including medication history and metabolic information, to tailor individualized weight management plans. The platform also offers regular telehealth visits, ensuring ongoing medical supervision and support for users. Additionally, patients are connected with certified health coaches who assist in determining the most effective medication combinations to achieve their weight loss goals. This innovative approach aims to provide comprehensive care from the convenience of patients' homes.

Sober Sidekick is a developer of a mobile application and telehealth platform focused on aiding individuals in their journey towards sobriety. The company provides a social networking environment where users can connect with others who share similar experiences and challenges related to addiction. By offering features such as a sobriety tracker and access to various addiction recovery resources, Sober Sidekick aims to support users in quitting alcohol and drugs. The platform fosters a judgment-free space that encourages accountability and community engagement, enhancing the recovery experience for those striving to maintain their sobriety.

Adora Health is a digital health company focused on supporting women's health, particularly during menopause. It has developed an application that utilizes natural language processing and artificial intelligence to provide personalized health management solutions. The platform offers a range of tools, including telehealth services, tailored advice, and lifestyle recommendations, all aimed at helping women navigate their health and well-being during this significant life stage. By integrating technology with women's health needs, Adora Health empowers users to make informed decisions regarding their nutrition and overall wellness.

Hypercare is a healthcare coordination platform designed to enhance clinical communication and collaboration among healthcare providers. Recognizing the challenges posed by traditional communication methods, such as switchboards and pagers, the platform aims to improve patient-centered care by enabling seamless connections across various healthcare settings, including hospitals, long-term care facilities, community care organizations, and family practices. Hypercare addresses the inefficiencies of existing communication channels by minimizing interruptions and allowing healthcare professionals to communicate and locate one another quickly and effectively. This innovative approach mitigates the risks associated with using non-secure messaging applications, thereby protecting patient privacy and reducing medico-legal liabilities for healthcare providers and institutions.

CalmiGo is a company that develops a portable, drug-free medical device aimed at providing immediate relief from emotional and mental distress. The device utilizes advanced technology to help users manage moments of anxiety, stress, and distress by regulating their breathing patterns and stimulating their senses. This innovative solution is designed to be accessible to individuals of all ages and varying technical abilities, allowing them to address anxiety-related issues effectively, regardless of their location. By focusing on a natural approach, CalmiGo offers a convenient and immediate alternative for those seeking relief without the use of medication.

Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.

Terapet SA is a Switzerland-based company founded in 2019 at CERN by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals. The company specializes in developing advanced proton therapy technology for cancer treatment, which allows for precise targeting of tumors while minimizing damage to surrounding healthy tissue. This innovative approach leverages the unique properties of protons, which stop at a predetermined depth within the patient, enabling the delivery of a concentrated dose to the tumor. Terapet's system also provides real-time, three-dimensional monitoring of the proton dose administered, enhancing treatment accuracy and safety. With a focus on making cutting-edge cancer therapy more accessible and cost-effective, Terapet is preparing for the market launch of its initial product.

Chiefy is a healthcare company based in New York that focuses on enhancing surgical safety and efficiency through its innovative perioperative team collaboration platform. Founded in 2020 by Maya Ber Lerner and Assaf Ziv, Chiefy aims to promote zero waste and zero harm in surgical procedures. The platform facilitates asynchronous virtual huddles, allowing surgeons, anesthesiologists, nurses, and other healthcare stakeholders to align on case plans before surgery. Additionally, it captures lessons, notes, and feedback post-procedure, fostering a culture of continuous improvement. By integrating quality and communication best practices into daily operations, Chiefy enables healthcare teams to collaborate more effectively, ultimately enhancing patient care and streamlining administrative tasks throughout the surgical journey.

Hi.health is a company focused on transforming the claims process in private health insurance by addressing inefficiencies and enhancing user experience. It offers a health insurance application that integrates secure payment methods with a range of digital services, including invoice and prescription management. By providing co-branded debit cards to insurers' members, Hi.health eliminates out-of-pocket expenses, allowing users to access health-related facilities globally. The platform delivers real-time data, reducing claims lag and operational costs while minimizing fraud. Additionally, it implements a rewards program to encourage cost-effective behavior among users. Ultimately, Hi.health aims to significantly improve the user experience for insurance members while helping insurers achieve substantial cost savings.

Magentiq Eye Ltd. is a medical device company based in Haifa, Israel, established in 2014. The company specializes in enhancing endoscopic procedures through advanced technologies such as artificial intelligence, deep learning, and computer vision. Its flagship product is the Automatic Polyp Detection System (APDS), which aids physicians during colonoscopy by automatically identifying suspicious polyp locations in real-time or in offline mode on pre-recorded videos. This innovation is designed to improve the accuracy of polyp detection, thereby reducing the miss-rate associated with colonoscopies, which can lead to interval cancer. Given the high volume of colonoscopy procedures performed annually, Magentiq Eye's solutions aim to enhance diagnostic effectiveness, ultimately contributing to better patient outcomes and significant healthcare cost savings. The APDS can be integrated with existing colonoscopy systems or offered as a service to clinics and hospitals, positioning Magentiq Eye as a key player in the medical device industry focused on improving endoscopic practices.

Sarcura GmbH is an Austrian deep-tech startup founded in 2019, specializing in the development of a machine platform for the large-scale, industrial manufacturing of personalized cell therapies aimed at treating cancer. The company employs advanced semiconductor technology and microfluidic processing to facilitate real-time process control and manipulation at the cellular level. This innovative approach enables a fully automated and modular manufacturing system, enhancing the efficiency and safety of cell therapies while making them more cost-effective for patients. Based in Hinterstoder, Austria, Sarcura is poised to transform manufacturing paradigms in the field of patient-specific cancer treatment.

Segmed, Inc. is a company based in Menlo Park, California, that specializes in providing cloud-based solutions for accessing curated and anonymized radiology data. Established in 2019, Segmed offers customized datasets tailored to the specific needs of its clients in the pharmaceutical and medical device sectors. Its platform supports the development of predictive models and enhances patient recruitment and data management, facilitating research and regulatory processes within the life sciences and technology industries. By focusing on de-identified and structured medical imaging data, Segmed aims to improve early disease detection and prediction while ensuring that findings are accessible and representative of diverse populations.

Ryver specializes in developing software solutions for data collaboration and sharing while prioritizing privacy. The company's platform enables clients to generate synthetic data from original datasets efficiently, particularly in the medical field, where it facilitates the rapid access to radiology cases. By automating the evaluation of privacy and utility of synthetic data, Ryver eliminates the need for manual compliance processes, significantly reducing the time and cost associated with data acquisition. Their technology seamlessly integrates into various data warehouses, cloud environments, and IT infrastructures, thereby providing detailed compliance and usage information. This innovative approach supports medical AI teams in creating high-quality radiology images with annotations, enhancing both speed and effectiveness in medical data utilization.

IMA Contigo, developed by BERDAC Smart Services S.L., is an innovative tablet dispenser designed to assist individuals in managing their medication schedules. Based in Barcelona, Spain, the device alerts users when it is time to take their medication, effectively reducing the risk of forgetfulness and errors in medication intake. By prioritizing user-friendliness, IMA aims to enhance patient adherence to prescribed treatments and ultimately improve health outcomes.

Leuko Labs, Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in the development of healthcare equipment. The company's primary product, PointCheck, is a non-invasive device designed to monitor and count white blood cells. This innovative technology allows for more frequent testing of immunosuppressed patients, such as those undergoing chemotherapy, enhancing their quality of life and clinical outcomes. The device is particularly beneficial as it eliminates the need for invasive blood draws and laboratory infrastructure, making it more accessible and convenient for patients.

Healee is a health technology company that specializes in delivering a comprehensive telehealth platform designed to streamline online consultations between patients and healthcare providers. The platform enhances patient-doctor communication by enabling users to track and share their health status while accessing medical advice through convenient virtual interactions. Healee's solution allows digital health innovators to implement customizable virtual care models tailored to various use cases. Its adaptable platform supports a fully-branded patient experience and integrates seamlessly with leading electronic health record systems, e-prescription services, billing, and other essential tools. This integration helps alleviate digital fatigue by consolidating multiple existing tools into one cohesive system, thereby aligning closely with clinical workflows and improving overall healthcare delivery.

Formulator is a mental healthcare platform designed to streamline the case formulation process for mental health professionals and their clients. By providing a structured tool, the platform enables individuals to articulate their situations and goals, facilitating effective communication with their clinicians from the outset. This approach enhances the productivity and accessibility of mental health care, allowing healthcare providers to address patients' core issues more efficiently. Formulator aims to simplify the initial steps of therapy, ultimately supporting better outcomes for clients and clinicians alike.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, founded in 2017. The company is focused on developing a metabolism-based liquid biopsy platform that aids in the early detection and monitoring of cancer. This platform employs a novel in vitro diagnostic laboratory assay kit and artificial intelligence algorithms, which analyze biomarkers in blood and urine to identify cancer signatures. Elypta's technology offers comprehensive profiling of glycosaminoglycan metabolites and includes scoring software to support a wide range of cancer applications, from screening to treatment response monitoring. The company is currently conducting clinical trials, particularly the AURORAX series, to investigate its platform's efficacy in renal cell carcinoma and other cancer indications, aiming to reduce cancer mortality through timely intervention.

QuantHealth is a company focused on enhancing drug development through artificial intelligence-based software. This software is designed to conduct patient-centric simulations that accelerate and de-risk the drug development process. By integrating diverse data points from the clinical and drug development landscape, QuantHealth predicts patient responses to both existing and new therapies. This capability allows pharmaceutical and biotechnology firms to explore various scenarios within their clinical trials, optimizing trial designs and improving the likelihood of successful outcomes. Ultimately, QuantHealth's solutions facilitate the discovery of new clinical opportunities and strategies for optimizing drug development.

MySecondEar is an e-commerce company specializing in hearing aids and accessories. It offers a digital platform that facilitates the entire hearing aid process, from consultation and initial fitting to fine adjustments, all conducted online. The company provides customers with a diverse selection of hearing aid options, enhancing their ability to engage with the world of sound. Additionally, MySecondEar employs hearing care professionals who are readily available to address any customer inquiries through an online inquiry form on their website, ensuring a comprehensive support system for users.

Taika3D Oy specializes in 3D design automation, particularly for the orthotics and prosthetics industry. The company's platform leverages 3D scanning and intelligent machine vision to rapidly capture images and generate 3D models, facilitating the creation of custom designs with remarkable speed and consistency. This innovation addresses the challenge of producing complex custom designs efficiently, significantly reducing design time by over 95%. Additionally, Taika3D’s technology enhances production scalability, minimizes errors and returns, and supports real-time design reviews. By streamlining the design process, Taika3D empowers laboratories to harness the advantages of 3D printing for mass customization, while also preserving the expertise of their teams. The applications of their technology extend beyond orthotics and prosthetics, encompassing various sectors that require precise and modular product creation.

MedaSystems is a developer of a cloud-based platform that facilitates the management of requests for experimental therapies. The company's platform streamlines processes by offering configurable workflows, a form builder for capturing complex and structured therapy-specific data, and tools for task management and tracking. Additionally, it integrates with machine learning libraries to enhance collaboration between manufacturers and physicians regarding requests for investigational medicines. MedaSystems focuses on various access programs, including expanded access, named patient programs, investigator-sponsored trial requests, and post-trial access, thereby empowering global initiatives in the healthcare sector.

Quantivly, Inc., established in 2019 and headquartered in Somerville, Massachusetts, specializes in developing artificial intelligence-based solutions tailored for the field of radiology. The company focuses on enhancing data liquidity and providing analytical tools that enable radiology providers to make informed decisions, thereby increasing access to medical imaging services. Quantivly's platform is designed to manage and analyze MRI imaging workflows by cleaning and harmonizing scanner data, resulting in a vendor-neutral and comprehensive source of operational knowledge. This innovative approach supports radiology departments and imaging centers in utilizing data analytics to improve decision-making, facilitate new research initiatives, and enhance the overall patient experience in healthcare.

Neuroute is an innovative company that specializes in an AI-powered platform aimed at enhancing the efficiency of clinical trials. The company has developed a web-based patient recruitment system that empowers healthcare innovators to connect with patients more effectively. By leveraging artificial intelligence, Neuroute generates targeted patient recruitment strategies and campaigns, facilitating the clinical development process. This approach not only improves the recruitment of participants for clinical trials but also aims to enhance the overall quality of patient care. Neuroute is supported by prominent industry players, reflecting its commitment to advancing healthcare through technology.

Zetta Genomics is a company based in Cambridge, England, founded in 2018, that focuses on managing large-scale genomic data for precision medicine. It operates a user-centric platform that facilitates direct connections between individuals and researchers, allowing users to share their personal health and genomic data. This platform supports research into a range of common disorders, such as eczema, diabetes, and depression, as well as rare diseases like muscular dystrophy. Zetta Genomics enables individuals to participate in studies with the choice to opt in or out, ensuring they have transparency and control over their data. The company utilizes distributed database technology and adheres to strict security practices to maximize the benefits of genomic data while maintaining data privacy.

Hi.health is a company focused on transforming the claims process in private health insurance by addressing inefficiencies and enhancing user experience. It offers a health insurance application that integrates secure payment methods with a range of digital services, including invoice and prescription management. By providing co-branded debit cards to insurers' members, Hi.health eliminates out-of-pocket expenses, allowing users to access health-related facilities globally. The platform delivers real-time data, reducing claims lag and operational costs while minimizing fraud. Additionally, it implements a rewards program to encourage cost-effective behavior among users. Ultimately, Hi.health aims to significantly improve the user experience for insurance members while helping insurers achieve substantial cost savings.

MedAll is a training platform designed for healthcare professionals and students, functioning as a virtual medical school. It provides healthcare organizations with the ability to deliver, store, and share their training courses, conferences, and teaching sessions in one centralized location, facilitating international access to educational resources. The platform also includes features for organizing training feedback, managing portfolios, and generating certificates, abstracts, and schedules. By streamlining these processes into a single paperless platform, MedAll aims to enhance the quality and accessibility of healthcare training globally.

Alfie Health is a virtual obesity management clinic that focuses on sustainable weight loss through a combination of precision medicine and behavioral change. Utilizing proprietary AI clinical decision support technology, Alfie Health continuously analyzes patient data, including medication history and metabolic information, to tailor individualized weight management plans. The platform also offers regular telehealth visits, ensuring ongoing medical supervision and support for users. Additionally, patients are connected with certified health coaches who assist in determining the most effective medication combinations to achieve their weight loss goals. This innovative approach aims to provide comprehensive care from the convenience of patients' homes.

Cardiomatics is a developer of advanced cloud-based artificial intelligence software specifically designed for the analysis of electrocardiogram (ECG) data. The company's medical-grade system utilizes proprietary algorithms that have been validated against both arrhythmia databases and clinical data, ensuring reliable and high-quality outcomes. By providing an easy-to-read reporting format, Cardiomatics enhances the diagnostic capabilities of healthcare providers and streamlines their workflows. The company collaborates with physicians, manufacturers, and ECG device providers on a global scale, positioning itself as a significant player in the digital health technology sector.

Lena Health is a developer of a text-based virtual assistant platform designed to assist patients, particularly those with chronic conditions. The platform utilizes conversational AI technology, supplemented by human support, to streamline care coordination and navigation tasks. By offering a SMS-text live chat option, Lena Health allows clinics to reduce long call queues, enabling patients to schedule appointments more conveniently. Additionally, the platform serves value-based care organizations and payers, helping them enhance medication adherence and improve overall health outcomes for their members. Through this innovative solution, Lena Health aims to facilitate a more efficient management of health tasks and improve patient engagement in their care.

The Lowdown is a London-based company that provides a comprehensive online platform focused on contraception and reproductive healthcare for women. Established in 2019, it enables users to share their experiences with various contraceptive methods, offering insights into their effects and side effects. By leveraging user-generated content alongside medical guidance, The Lowdown empowers women to make informed decisions regarding their healthcare. The platform allows women to report their personal experiences, check symptoms related to their contraceptive methods, and access practical advice to mitigate any negative emotional or mental impacts. This community-driven approach prioritizes women's autonomy in managing their reproductive health.

Promptly Health is a health data analytics company that specializes in collecting, integrating, and analyzing data related to healthcare outcomes. The company has developed proprietary technology aimed at enhancing patient engagement and facilitating real-world data collection and outcomes analytics. By discovering digital biomarkers associated with critical symptoms, adverse effects, and treatment outcomes, Promptly Health provides valuable insights into patient care. Its technology not only anticipates patient experiences before starting treatments but also allows for tracking progress throughout the treatment process. This comprehensive approach offers validated information on clinical conditions, symptoms, recovery, and healthy living strategies, ultimately enabling patients to monitor the outcomes of their medical treatments effectively. Through collaborations with innovative healthcare organizations, Promptly Health aims to improve healthcare quality while reducing costs for numerous patients.

EarlySight SA is a Swiss medical device company established in 2016 and headquartered in Lausanne. It specializes in developing advanced imaging technology to aid in the early detection and treatment of eye diseases. The company's innovative eye fundus camera utilizes cellular-level imaging and transscleral illumination to provide detailed images of the retina, allowing for the detection of minor structural changes. This technology enables eye specialists to monitor treatment effects rapidly and non-invasively, enhancing their ability to visualize the morphology of retinal cells. EarlySight aims to bring its cutting-edge solutions to clinics, thereby improving patient outcomes in ophthalmology.

MoveUP is a company focused on developing and commercializing digital therapeutics solutions designed to enhance healthcare delivery. Its innovative platform features a closed-loop system that ensures high compliance and improved outcomes for patients. By continuously collecting data, the platform personalizes treatment plans, significantly enhancing patient satisfaction. MoveUP's initial product targets orthopedic patients recovering from joint surgery, providing a user-friendly medical-grade mobile application that supports faster recovery. The company holds CE medical device and ISO 13485 certifications, underscoring its commitment to quality and regulatory standards in the healthcare sector.

Contextflow GmbH is a Vienna-based company that specializes in developing machine learning and artificial intelligence solutions for radiology image search and analysis. Founded in 2016, Contextflow has created a 3D image-based search engine that allows radiologists to quickly identify regions of interest within medical images, specifically targeting over 18 patterns in lung CT scans. The technology enables the rapid retrieval of visually similar cases, relevant descriptions, and differential diagnoses, thereby streamlining the decision-making process for healthcare professionals. Contextflow's software enhances diagnostic workflows and integrates seamlessly into existing PACS systems, ultimately improving patient care. The company has formed strategic partnerships with notable organizations, including the Radiology Center and Boehringer Ingelheim, and has garnered recognition for its innovative approach, such as being awarded the Most Promising Startup distinction. Currently, Contextflow is testing its solutions with multiple partners and aims to expand its international presence in the near future.

Replica Analytics Ltd. is a Canadian company based in Ottawa that specializes in developing modeling software to create synthetic data derived from real clinical datasets. Founded in 2019, the company employs advanced machine learning technologies to generate privacy-protective synthetic data that retains the statistical properties of the original data. This platform not only facilitates the creation of high-utility synthetic datasets but also provides documentation regarding the utility characteristics of the data. By doing so, Replica Analytics enables businesses to access valuable data while adhering to global regulatory requirements for privacy protection and data analysis.

BioLib Technologies ApS is a Copenhagen-based company founded in 2019 that operates a biomedical data analysis platform focused on biological and health data. The company provides end-to-end bioinformatic data analytics, offering access to comprehensive datasets, analytic workflows, algorithms, and cloud-computing infrastructure. BioLib enables scientists and data holders to collaborate securely and efficiently, facilitating the analysis of genomic and healthcare data. By delivering a zero-knowledge analysis platform, BioLib accelerates the transition from raw experimental data to actionable insights, thereby supporting the development of new treatments and diagnostics and enhancing the pace of scientific discovery.

Segmed, Inc. is a company based in Menlo Park, California, that specializes in providing cloud-based solutions for accessing curated and anonymized radiology data. Established in 2019, Segmed offers customized datasets tailored to the specific needs of its clients in the pharmaceutical and medical device sectors. Its platform supports the development of predictive models and enhances patient recruitment and data management, facilitating research and regulatory processes within the life sciences and technology industries. By focusing on de-identified and structured medical imaging data, Segmed aims to improve early disease detection and prediction while ensuring that findings are accessible and representative of diverse populations.

PlenOptika, Inc. is a technology company based in Allston, Massachusetts, that specializes in the development of a handheld device called QuickSee, which provides accurate eyeglass prescriptions through precise refractive measurements. Founded in 2014 as a spin-off from the Massachusetts Institute of Technology, the company addresses the significant global issue of low vision affecting over one billion people. QuickSee is designed to facilitate optometry, especially in rural and resource-limited settings, by simplifying the process of vision correction. The device captures the eye's full aberration fingerprint, effectively reducing the costs and physical space required by traditional autorefractors. PlenOptika aims to make eye care accessible to underserved communities worldwide and has received recognition from various social innovation foundations and business competitions for its contributions to healthcare technology.

Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, specializing in AI-powered medical imaging solutions. Founded in 2017, the company develops innovative software products such as SubtleMR and SubtlePET, which are designed to enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. These products utilize proprietary deep learning algorithms to reduce image noise and improve sharpness, thereby increasing efficiency and safety in clinical workflows. Subtle Medical's technology is FDA cleared and CE marked, and it operates on a vendor-agnostic AI infrastructure that integrates seamlessly with existing imaging systems. The company's mission is to enhance the quality, value, and accessibility of medical imaging by lowering costs, reducing imaging time, and minimizing radiation and contrast doses for patients.

Sarcura GmbH is an Austrian deep-tech startup founded in 2019, specializing in the development of a machine platform for the large-scale, industrial manufacturing of personalized cell therapies aimed at treating cancer. The company employs advanced semiconductor technology and microfluidic processing to facilitate real-time process control and manipulation at the cellular level. This innovative approach enables a fully automated and modular manufacturing system, enhancing the efficiency and safety of cell therapies while making them more cost-effective for patients. Based in Hinterstoder, Austria, Sarcura is poised to transform manufacturing paradigms in the field of patient-specific cancer treatment.

EarlySight SA is a Swiss medical device company established in 2016 and headquartered in Lausanne. It specializes in developing advanced imaging technology to aid in the early detection and treatment of eye diseases. The company's innovative eye fundus camera utilizes cellular-level imaging and transscleral illumination to provide detailed images of the retina, allowing for the detection of minor structural changes. This technology enables eye specialists to monitor treatment effects rapidly and non-invasively, enhancing their ability to visualize the morphology of retinal cells. EarlySight aims to bring its cutting-edge solutions to clinics, thereby improving patient outcomes in ophthalmology.

Methinks is a developer of a medical imaging platform that leverages advanced artificial intelligence techniques to enhance the diagnosis of brain-related diseases, particularly acute stroke. Utilizing Google's deep learning framework, Tensorflow, Methinks analyzes neuroimaging data to facilitate accurate and timely diagnoses. The platform offers a significant advantage by enabling stroke assessments through non-contrast CT scans, thereby eliminating the need for contrast CT and reducing the time required for treatment. This innovative approach enhances communication between radiologists, hospitals, stroke units, and other healthcare professionals, ultimately aiming to improve clinical outcomes in stroke care.

Terapet SA is a Switzerland-based company founded in 2019 at CERN by physicists Christina Vallgren and Marcus Palm, along with Professor Raymond Miralbell from the Geneva University Hospitals. The company specializes in developing advanced proton therapy technology for cancer treatment, which allows for precise targeting of tumors while minimizing damage to surrounding healthy tissue. This innovative approach leverages the unique properties of protons, which stop at a predetermined depth within the patient, enabling the delivery of a concentrated dose to the tumor. Terapet's system also provides real-time, three-dimensional monitoring of the proton dose administered, enhancing treatment accuracy and safety. With a focus on making cutting-edge cancer therapy more accessible and cost-effective, Terapet is preparing for the market launch of its initial product.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.

Contextflow GmbH is a Vienna-based company that specializes in developing machine learning and artificial intelligence solutions for radiology image search and analysis. Founded in 2016, Contextflow has created a 3D image-based search engine that allows radiologists to quickly identify regions of interest within medical images, specifically targeting over 18 patterns in lung CT scans. The technology enables the rapid retrieval of visually similar cases, relevant descriptions, and differential diagnoses, thereby streamlining the decision-making process for healthcare professionals. Contextflow's software enhances diagnostic workflows and integrates seamlessly into existing PACS systems, ultimately improving patient care. The company has formed strategic partnerships with notable organizations, including the Radiology Center and Boehringer Ingelheim, and has garnered recognition for its innovative approach, such as being awarded the Most Promising Startup distinction. Currently, Contextflow is testing its solutions with multiple partners and aims to expand its international presence in the near future.

Segmed, Inc. is a company based in Menlo Park, California, that specializes in providing cloud-based solutions for accessing curated and anonymized radiology data. Established in 2019, Segmed offers customized datasets tailored to the specific needs of its clients in the pharmaceutical and medical device sectors. Its platform supports the development of predictive models and enhances patient recruitment and data management, facilitating research and regulatory processes within the life sciences and technology industries. By focusing on de-identified and structured medical imaging data, Segmed aims to improve early disease detection and prediction while ensuring that findings are accessible and representative of diverse populations.

Neurescue ApS, headquartered in Copenhagen, Denmark, specializes in developing innovative medical devices aimed at addressing cardiac arrest and hemorrhage. Established in 2014, the company has introduced its flagship product, the safeREBOA device, which is recognized as the first computer-aided aortic occlusion catheter designed to enhance the care of emergency patients. Neurescue's commitment lies in improving resuscitation rates and extending critical treatment time through advanced cardiovascular solutions. The organization is focused on advancing the clinical utility of its devices to ultimately save lives in emergency situations.

Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, founded in 2017. The company is focused on developing a metabolism-based liquid biopsy platform that aids in the early detection and monitoring of cancer. This platform employs a novel in vitro diagnostic laboratory assay kit and artificial intelligence algorithms, which analyze biomarkers in blood and urine to identify cancer signatures. Elypta's technology offers comprehensive profiling of glycosaminoglycan metabolites and includes scoring software to support a wide range of cancer applications, from screening to treatment response monitoring. The company is currently conducting clinical trials, particularly the AURORAX series, to investigate its platform's efficacy in renal cell carcinoma and other cancer indications, aiming to reduce cancer mortality through timely intervention.

PlenOptika, Inc. is a technology company based in Allston, Massachusetts, that specializes in the development of a handheld device called QuickSee, which provides accurate eyeglass prescriptions through precise refractive measurements. Founded in 2014 as a spin-off from the Massachusetts Institute of Technology, the company addresses the significant global issue of low vision affecting over one billion people. QuickSee is designed to facilitate optometry, especially in rural and resource-limited settings, by simplifying the process of vision correction. The device captures the eye's full aberration fingerprint, effectively reducing the costs and physical space required by traditional autorefractors. PlenOptika aims to make eye care accessible to underserved communities worldwide and has received recognition from various social innovation foundations and business competitions for its contributions to healthcare technology.

TeiaCare is a health technology company focused on enhancing the long-term care sector through the use of artificial intelligence. The company has developed ANCELIA, an advanced AI solution that automatically collects and analyzes data on the conditions of residents in care homes. This technology empowers healthcare workers and managers by improving daily assistance activities and allowing for the delivery of higher quality care to a greater number of residents without additional effort. By leveraging data, TeiaCare provides valuable insights and reports that optimize decision-making and management processes within nursing homes. The company emphasizes a new care model based on personalized assistance, objective data, and transparency, aiming to address inefficiencies in monitoring post-acute hospital patients and ensuring better outcomes for residents.

Contextflow GmbH is a Vienna-based company that specializes in developing machine learning and artificial intelligence solutions for radiology image search and analysis. Founded in 2016, Contextflow has created a 3D image-based search engine that allows radiologists to quickly identify regions of interest within medical images, specifically targeting over 18 patterns in lung CT scans. The technology enables the rapid retrieval of visually similar cases, relevant descriptions, and differential diagnoses, thereby streamlining the decision-making process for healthcare professionals. Contextflow's software enhances diagnostic workflows and integrates seamlessly into existing PACS systems, ultimately improving patient care. The company has formed strategic partnerships with notable organizations, including the Radiology Center and Boehringer Ingelheim, and has garnered recognition for its innovative approach, such as being awarded the Most Promising Startup distinction. Currently, Contextflow is testing its solutions with multiple partners and aims to expand its international presence in the near future.

MindPeak GmbH is a technology company based in Hamburg, Germany, founded in 2018. It specializes in developing artificial intelligence software tools aimed at enhancing the accuracy and efficiency of cancer diagnostics. The company's flagship product, BreastAI, is designed for the quantification of breast cancer immunohistochemistry (IHC) and can be integrated into third-party software systems. MindPeak's solutions automate tissue diagnostics, enabling pathologists to identify and quantify tumorous regions and detect breast cancer cells more effectively. By streamlining tasks such as cell and biomarker quantification, MindPeak's tools allow cancer specialists to focus on critical decision-making in clinical environments, ultimately improving patient care while making diagnostic processes more accessible and cost-effective.

Kheiron Medical Technologies is a company based in London, United Kingdom, with additional locations in San Francisco, California, Budapest, Hungary, and Amsterdam, Netherlands. It was incorporated in 2016 and develops Mia, an intelligent assessment tool designed to assist radiologists in detecting breast cancer through mammography. The company employs artificial intelligence and human insight to enhance the efficiency, consistency, and accuracy of radiology reporting. Kheiron's mission is to improve outcomes for cancer patients by pioneering precision radiology, with a current focus on breast cancer screening.

Leuko Labs, Inc., established in 2017 and headquartered in Boston, Massachusetts, specializes in the development of healthcare equipment. The company's primary product, PointCheck, is a non-invasive device designed to monitor and count white blood cells. This innovative technology allows for more frequent testing of immunosuppressed patients, such as those undergoing chemotherapy, enhancing their quality of life and clinical outcomes. The device is particularly beneficial as it eliminates the need for invasive blood draws and laboratory infrastructure, making it more accessible and convenient for patients.